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Abstract: M. tuberculosis (Mtb), which causes tuberculosis disease, continues to be a major global
health threat. Correct identification of valid drug targets is important for the development of
novel therapeutics that would shorten the current 6–9 month treatment regimen and target resistant
bacteria. Methionine aminopeptidases (MetAP), which remove the N-terminal methionine from
newly synthesized proteins, are essential in all life forms (eukaryotes and prokaryotes). The MetAPs
contribute to the cotranslational control of proteins as they determine their half life (N-terminal end
rule) and facilitate further modifications such as acetylation and others. Mtb (and M. bovis) possess
two MetAP isoforms, MetAP1a and MetAP1c, encoded by the mapA and mapB genes, respectively.
Conflicting evidence was reported in the literature on which of the two variants is essential. To resolve
this question, we performed a targeted genetic deletion of each of these two genes. We show that a
deletion mutant of mapA is viable with only a weak growth defect. In contrast, we provide two lines
of genetic evidence that mapB is indispensable. Furthermore, construction of double-deletion mutants
as well as the introduction of point mutations into mapB resulting in proteins with partial activity
showed partial, but not full, redundancy between mapB and mapA. We propose that it is MetAP1c
(mapB) that is essentially required for mycobacteria and discuss potential reasons for its vitality.
Keywords: Methionine aminopeptidase; tuberculosis; mycobacteria; gene essentiality; ribosome
1. Introduction
Mycobacterium tuberculosis-complex bacteria are a major cause of morbidity and mortality in the
developing as well as the developed world [1]. Control of the disease is hindered by the emergence of
highly antibiotic-resistant strains as well as by the pathogens’ ability to enter a persistent state where it
tolerates conventional antibiotics even in the absence of genetic drug-resistance [2], necessitating long,
complicated treatment regimens. Novel drugs are in dire need and the discovery and validation of
new drug-targets are therefore of high importance.
Methionine aminopeptidase (MetAP, previously MAP) is a metallo-protease that removes the
N-terminal methionine from newly synthesized proteins. This co-translational control mechanism is
conserved in all life forms from bacteria to high vertebrates and plants [3]. There are two classes of this
enzyme—MetAP1 and MetAP2 and humans possess them both. MetAP1, which is more prevalent in
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prokaryotes, is further subdivided into four subtypes—MetAP1a, b, c and d [4]. The gram negative
bacteria E. coli and S. typhimurium, for example, have one copy of a MetAP1a and its function was shown
to be indispensable for viability [5,6]. M. tuberculosis (like other actinobacteria) has two MetAP1 genes:
MetAP1a (mapA, Rv0734 in H37Rv, Mb0755 in M. bovis) and MetAP1c (mapB, Rv2861c, Mb2886c). The
main difference between them is an additional N-terminal stretch of 40 amino acids in MapB which is
thought to play a role in the interaction with the ribosome [7]. The essentiality of the MetAP pathway
was never formally proven in Mtb, although the outcome of studies with other organisms makes this a
likely assumption. Which of the two genes in Mtb is essential or whether they are synthetically lethal
are questions derived from conflicting reports: one study [8], using chemical inhibition of both enzymes,
showed marked reduction of bacterial viability, however no complete lethality, possibly due to incomplete
inhibition. A knock-down of each of these genes separately by expressing antisense RNA suggested that
mapA (MetAP1a) was more important for viability as a knockdown of mapB (MetAP1c) using the same
method had only a little effect, suggesting that mapB was less important. In contrast, analysis of a high
density transposon-mutant library in Mtb [9] suggested that mapA was not essential, whereas mapB was.
A targeted gene deletion experiment to clarify this conundrum was not performed. Since essential genes
are an attractive target for drug development (especially genes coding for enzymes that could potentially
be inhibited), it is imperative to pinpoint which of these two genes is the essential one in order to focus
inhibitor development on the correct isoform [10]. We therefore intended to delete each of the two genes
in order to firmly establish which is the essential, whether only the inhibition of both genes/inactivation
of both isoforms leads to a lethal phenotype (synthetic lethality), or whether the MetAP pathway is
completely non-essential in mycobacteria. We created a double mapA/mapB deletion mutant and continued
to create point mutations of the genes affecting their activity to test the minimal requirements for viability.
2. Materials and Methods
2.1. Bacteria and Growth Conditions
We used M. tuberculosis-complex bacteria, M. bovis BCG pasteur. Bacteria were grown in standard
7H9 media or on 7H10 plates supplemented by 0.05% glycerol, 10% ADS (Albumin-Dextrose-NaCl)
and tween80 (for 7H9 only). Antibiotic concentrations for mycobacteria were 50 µg/ml (hygromycin),
20 µg/ml (kanamycin and streptomycin) and 17–25 µg/ml (zeocin). ATc (Anhydrotetracycline) was
added when appropriate in concentrations of 50 ng/ml.
2.2. Gene Introduction and Deletion
Plasmid introduction into mycobacteria was performed by electroporation, as previously
widely described. Gene deletions were performed by the temperature-sensitive transducing
mycobacteriophage technique, also previously described [11]. Briefly, the 600 bp regions flanking
the gene of interest were PCR amplified, the sequence was confirmed, cloned on either side of
the resistance marker on either pMSG360 (hygromycin) or pMSG360Z (Zeocin) and the resulting
plasmid was digested by DraI and AflII, producing a linear piece of the knock-out construct flanked
by areas homologous to the temperature-sensitive, TM4-based, phAE87. This linear fragment was
electroporated into 42 ◦C-induced EL350 bacteria (E. coli expressing recombineering enzymes, induced
at 42 ◦C) that also carry the phagemid of phAE87. Successful recombinant EL350 were isolated on
antibiotic selective plates, the phagemid was extracted by phenol-chloroform, electroporated into M.
smegmatis bacteria and plated for plaques in permissive 30 ◦C temperature. Plaques were picked,
presence of KO construct was confirmed by PCR and it was amplified to infect target BCG bacteria at
39 ◦C. After infection, BCG bacteria were plated on antibiotic selective plates (with ATc when needed)
and grown at 37 ◦C in 5% CO2 for 3–4 weeks.
The V18G and W255L mutations in mapB were introduced by a two-step PCR reaction where the
primers in the first reaction contained the desired single nucleotide change. Correct sequence was
confirmed by Sanger sequencing.
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2.3. Expression and Purification of Recombinant MapB Proteins
Wild-type mapB and the mutant mapBV18G, W255L were cloned with a HIS-tag at their N-termini
into the pET29a expression vector. The wild type protein was expressed and purified as described
in “The QIAexpressionist™—A handbook for high-level expression and purification of 6xHis-tagged
proteins”. Hilden, Germany: Qiagen, June 2013. The recombinant MapBV18G;W255L was expressed and
purified as follows: E. coli Rosetta cells, harboring the expression plasmid, were grown at 37 ◦C to an
OD600 (Optical Density) of 0.5 and then induced by 1 mM IPTG. After Induction, cells were grown at
30 ◦C for 3 h before collecting the cell pellet by centrifugation at 4 ◦C for 15 min at 5000 g. Expression
of the protein was checked by SDS-PAGE. Purification of the insoluble MapBV18G;W255L mutant from
E. coli cells: Proteins were purified under denaturing conditions according to the QIAexpressionist
protocol (Qiagen) using an 8 M urea buffer and a nickel-nitrilotriacetic acid agarose. After purification,
the proteins were applied dropwise to a refolding buffer (400 mM Arg-HCL, 1 mM EDTA, 3 mM
reduced glutathione, 0.3 mM oxidized glutathione and 0.1 M Tris, pH 8) for a series of three days at
4 ◦C with stirring. After three days, the refolding buffer protein mixture was dialyzed against 5 L TBS
(150 mM NaCl, 50 mM Tris-HCl, pH 7.6) with SnakeSkin Dialysis Tubing (Thermo fisher) for 12 h at
4 ◦C. After dialysis, the protein solution was concentrated with Amicon Ultra-4 Centrifugal Filter Units
(Merck-Millipore) and examined by SDS-PAGE.
2.4. Activity of the Recombinant Proteins Assessment
Activity was assayed with the fluorogenic substrate Met-MCA (Peptide Institute, Inc). The removal
of the methionine was continuously measured by fluorescence (excitation wavelengths = 355 nm,
emission wavelength 460 nm). Recombinant protein (0.2 µM) was incubated on ice for 10 min in
the assays buffer (50 mM Tris-HCL, 1 mM DTT, 1.5 mM MgCl2, pH 7.4). The assay was started by
adding of the Met-MCA (final concentration 400 µM) substrate to the assay buffer protein mixture
and was performed at room temperature. The measurement was done with an F7000 (Hitachi)
Flourescence Spectrophotometer.
3. Results
3.1. mapA (Rv0734, Mb0755) is Dispensible for Bacterial Viability
In order to examine the essentiality of mapA, we took an unbiased approach in which we first
pre-complemented wild-type (wt) bacteria with an additional copy of mapA at the L5 phage attB site
(attB), creating a mutant with two copies of the gene. To have a better ability to perform depletion
studies, the complementing gene was placed under a tetracycline controlled promoter which can be
induced by the addition of anhydrotetracycline (ATc), whereas withdrawal of ATc allows only for
weak, if any, expression [12]. This construct was placed under kanamycin selection in the plasmid
pDB116 and electroporated into BCG-Pasteur, creating the mutant mDB25 [pasteur attb:kan:mapA-ATc].
We then proceeded to deleting the native mapA gene, replacing it with a hygromycinR cassette, using a
specialized transducing phage based on phAE87 (TM4) designated phDB20 [11,13]. After infection
with phDB20, bacteria were plated on 7H10 plates with hygromycin and ATc. Six hygromycin resistant
colonies appeared and all were picked and analyzed by PCR. A PCR using primers koA-F and koA-R
(binding outside of the flanking regions used to create the deletion) would result in a 2.0 kb fragment
in wt, however a 2.9 kb fragment in a mutant where successful replacement of mapA by hygR took
place. All six colonies showed a 2.9 kb fragment (Figure 1a); one of them (clone 4) was arbitrarily
chosen for further analysis and examined by sequencing. The flanking regions of the native mapA on
both sides were found, however the mapA gene itself, except the first and last 30 bp, was replaced by
the hygromycinR gene. The mapA deletion and replacement by hygromycinR was additionally shown by
several digestions of the PCR product of the locus (Supplementary Figure S1). The mutant was called
mDB59 [Pasteur ∆mapA:hygR, attb:kan:mapA-ATc].
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Figure 1. (A) Creation and confirmation of a mapA deletion mutant. After infection with phDB20, six 
hygromycin resistant colonies were analyzed by PCR. All six produced a pattern consistent with 
mapA deletion and colony four was named mDB59. (B,C) mDB59 is not dependent on ATc for 
growth. (B) mDB59 was grown with (leftmost tube) and without (middle tube) ATc (inducing the 
expression of mapA) in liquid. The rightmost tube is clear 7H9 media. (C) Left–with ATc, Right–no 
ATc. No difference in growth is apparent. 
Figure 1. (A) Creation and co firmation f a map letion mu ant. Aft r infec ion with phDB20, six
hygromycin resistant colonies were analyzed by PCR. All six produced a pattern consistent with mapA
deletion and colony four was named mDB59. (B,C) mDB59 is not dependent on ATc for growth. (B)
mDB59 was grown with (leftmost tube) and without (middle tube) ATc (inducing the expression of
mapA) in liquid. The rightmost tube is clear 7H9 media. (C) Left–with ATc, Right–no ATc. No difference
in growth is apparent.
To test whether mapA was essential, we first opted for transcription silencing by withdrawal of
ATc, resulting in abrogation of mapA expression. We grew mDB59 in 7H9 media with or without ATc
and also plated it on 7H10 plates with and without ATc. Interestingly, and in contrast to the previous
reports on mapA essentiality, bacteria grew well with or without the addition of ATc—both on 7H10
plates and in 7H9 media (always after repeated washes to remove traces of ATc in media) (Figure 1b,c).
This result could be explained by (i) non-essentiality of mapA, (ii) (in case mapA is essential) by an
"escape" of mapA from the ATc-controlled expression, or (iii) low-level expression resulting from a
leaky promotor control, allowing enough MapA expression for the survival of the bacteria. To unravel
the correct possibility, it was intended to completely remove the complementing mapA sequence from
the bacterial chromosome [14]. For this purpose, we used two additional plasmids: pDB19 (an empty
attP-integrating plasmid, conferring resistance to zeocin) and pDB249 (the same plasmid containing the
mapA gene). We separately electroporated both plasmids into mDB59 and plated them on zeocin plates.
If mapA was essential, we expected to get colonies with pDB249 electroporation only as the exchange for
pDB19 would create a null-mutant. Alternatively, if it was not essential, then the exchange of pDB116
for both pDB249 and pDB19 would be possible and we would get zeocin resistant colonies in both
electroporations. Indeed, both electroporation yielded dozens of colonies (Figure 2a). We arbitrarily
picked two colonies from each plate and examined them by PCR. The results show that all four colonies
(two mDB59 + pDB19, two mDB59 + pDB249) acquired the zeocin resistance gene, with the pDB19 or
pDB249 replacing the previously integrated cessette (which contained mapA). This replacement led
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to the loss of mapA for the two [mDB59 + pDB19] colonies and created a complete mapA null strain
(Figure 2b). One of the full-deletion colonies was named mDB77 (∆mapA;hyg, attb:zeo), whereas one of
the [mDB59 + pDB249] colonies was called mDB78 (∆mapA;hyg, attb:mapA:zeo). The growth of mDB77
(full deletion mutant) was slightly slower during the exponential phase relative to that of mDB78
(Figure 2c). However, the same final OD was reached.
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Figure 2. Complete mapA deletion mutant. (A) Electroporation of mDB59 with either pDB19 or pDB249
(exchanging mapA-Kan for null-zeocin or mapA-zeocin, respectively) both yielded multiple colonies.
(B) Two random colonies from each electroporati n were analyzed by PCR. All four olonies became
zeo-R positive (left panel, zeo-R product is 0.35KB), confirming cassette exchange, however only mDB59
+ pDB249 remains positive for mapA (Right, expected PCR product of 0.5KB). Both mDB59 + pDB19
colonies are complete mapA deletion mut nt . (C) A complete mapA deletion mu ant (mDB77) has a
mild growth defect in 7H9 media during the exponential phase of growth as compared to mDB78,
however it reaches the same final OD (done in duplicates, one of two similar experiments is shown).
3.2. mapB (Rv 2861c, Mb2886c) is Genetically Essential for Bacterial Viability
As mapA was shown not to be essential, we opted for a similar unbiased approach towards
mapB essentiality. We first pre-complemented BCG pasteur with pDB144, which is an attB integrating,
kanamycin-selected plasmid, carrying a copy of mapB with its native promotor, thus creating mDB26
(BCG Pasteur attb:mapB:kan). We then proceeded to delete the native mapB gene using the phage
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phDB13, replacing mapB with a zeocinR cassette. After infection with the phage, bacteria were plated
on 7H10 plates with zeocin, and a resistant colony was picked and analyzed in a similar manner to
the mapA deletion. Because the zeocinR gene is shorter than the hygromycinR gene, the PCR product of
primers flanking mapB (including 700 bases from both sides/flanks) in wt bacteria is only 100bp shorter
than the product in a correct deletion mutant (Figure 3a), making a definitive proof of the deletion more
difficult, and thus we sent the PCR product for sequencing. The flanking regions of mapB were present
at both sides of the PCR product, however the mapB gene itself was replaced by the zeocinR gene. Also,
replacement of mapB by zeocinR can be distinguished from wt by HindIII and SmaI digestions of the
PCR product (Figure 3b). The correct deletion mutant was named mDB40 (∆mapB:zeo, attb:mapB:kan).
To examine if mapB was essential or not, we again attempted to remove the complementing mapB gene
from the attB site by exchanging it with either one of two plasmids: an empty, hygromycin-selected
pYUB412, or the same vector with wt mapB on it (pDB271). In contrast to the mapA experiment, this time
we got multiple colonies only in the electroporation with mDB271 (when mapB was simply replaced by
another copy), whereas electroporation with pYUB412 yielded no colonies, despite several attempts and
long incubation times (Figure 4). One of the clones where mapB:kana was replaced by pDB271 (mapB:hyg)
was called mDB105 (∆mapB:zeocin; attB:mapB:hygromycin) and was used for further experiments. We
also conducted a similar experiment, this time with the empty streptomycin-selected vector pDB60
and the same vector with wt mapB (pDB231). Again, whereas multiple streptomycin resistant colonies
were obtained with pDB231, we did not succeed with pDB60 (Supplementary Figure S2). One of the
pDB231-electroporated colonies was called mDB55 (∆mapB:zeocin; attB:mapB:streptomycin), and was
also used for further experiments.Cells 2019, 8, x 8 of 14 
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(0.9, 0.7, 0.3KB in wt, 1.05, 1.05 in deletion mutant) confirms the correct allelic exchange in mDB40 (see
diagram in (C)).
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To confirm that mapB expression was indeed essential, an additional approach was undertaken
by using the newly created mDB55 (∆mapB:zeo, attb:mapB:strep): we constructed a single-copy,
kanamycin-selected, episomal plasmid (pDB261), expressing mapB. The origin of replication of this
plasmid is the MF1 origin, which would be rapidly lost when its presence is not selected by an
existing/included antibiotic or another essential gene [15]. The successful introduction of pDB261
into mDB55 was confirmed by PCR and the mutant was called mDB103 (∆mapB:zeo, attb:mapB:strep,
MF1:mapB:kana). Then, the mapB cassette at the attb site was exchanged with either an empty
hygromycinR cassette (pYUB412), creating mDB108 (∆mapB:zeo, attb:hyg, MF1:mapB:kana), or a similar
cassette designated pDB271 containing another mapB copy, creating mDB107 (∆mapB:zeo, attb:mapB:hyg,
MF1:mapB:kana). This approach allowed us to test whether the bacterium can lose its copy of mapB
if it does not have an additional copy. We grew both mDB107 and mDB108 for 12 doubling times
without kanamycin with the option to lose the pDB261 plasmid in case mapB is not essential. We
then plated for and examined single colonies for kanamycin resistance. As expected, ~75% of the
mDB107 colonies [attb:hyg:mapB] lost their kanamycin resistance (23 colonies grew on kana + hyg, as
opposed to 98 colonies on hygromycin alone) as there was no selection pressure for the retention of
pDB261. In contrast, all of mDB108 [attb:hyg] mutants retained pDB261 with its kanamycin resistance
(86 colonies on kana + hyg and 90 colonies on hygromycin alone), as the pDB261 plasmid was their
sole source of mapB expression and MapB activity.
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Figure 4. mapB is essential in BCG. mDB40 [pasteur ∆mapB:zeo, attb:kana:mapB] was electroporated by
either pYUB412 (attb:hyg, left) or pDB271 (attb:hyg:mapB, right). Multiple colonies arise with pDB271
where mapB is replaced by another copy of the same gene. However, pYUB412 would have yielded a
null-mapB mutant. No colonies arise on that plate.
These results indicate that in contrast to the previous chemical inhibition report and in agreement
with the transposon-mutant library analysis, mapB, and not mapA, is the essential MetAP gene in M.
bovis BCG (and probably in all M. tubercu losis-Complex bacteria).
3.3. Creation of a Double Map Mutant
To further explore the role of the two map genes and to clarify whether they can compensate for
each other, we decided to create a double mutant ∆mapA ∆mapB. Because the complete ∆mapB
mutant is not viable, we started off with the mDB78 mutant, described earlier in this report
(∆mapA:loxP-hygromycinR-loxP; attb:zeocinR:mapA). We first "cured" mDB78 of the hygromycinR gene by
introducing a kanamycin-selected, MF1-origin plasmid named pMSG381 which has the cre-recombinase
on it [16]. After the loss of pMSG381 (MF1-origin plasmids are rapidly lost without the antibiotic
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selection pressure), the hygromycinR-cured mutant was named mDB122 (∆mapA:loxP; attb:zeocinR:mapA).
We then changed the attb cassette for an additional copy of mapB (pDB271), creating the mDB128 strain
(∆mapA:loxP; attb:hygromycinR:mapB), and used phDB13 to delete mapB from this mutant, creating
mDB130 (∆mapA:loxP; ∆mapB:zeocinR; attb:hygromycinR:mapB). The deletion of the native mapB was
confirmed using the same methods as the single-deletion mapB mutant (mDB40).
3.4. Complementation of ∆mapB Mutants with mapB with Reduced Enzymatic Activity
As we confirmed mapB is essential for M. bovis growth, we wanted to examine whether knockout
mutants are rescued by expression of MAP with modified activity. It was previously reported that
MapBV18G and MapBW255L were highly defective in their methionine aminopeptidase activity as the
substitution W255L affects the catalytic pocket, whereas V18G affects the N-terminus extension of the
protein [17]. We first designed these two mutation sequences separately and also a mapB sequence
containing both point mutations: mapBV18G, mapBW255L and mapBV18G;W255L. We expressed wild-type
MapB and the MapBV18G;W255L protein in E. coli, purified it and tested the activity in vitro. We found
MapBV18G;W255L had approximately 8% activity of the wt protein (Figure 5 and Supplementary Table S1).Cells 2019, 8, x 10 of 14 
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Figure 6. (A) when MapA is present, MapB can be replaced with MapBV18G (pDB268, top right),
MapBW255L (pDB269, bottom left) or MapBV18G;W255L (pDB296, bottom right), however not completely
removed (pDB266, empty vector. Top left). (B) On the background of mapA deletion, MapB can still
be replaced by MapBV18G (pDB338, middle plate), MapBW255L (pDB339, left plate) a d not an empty
v ctor (pDB170, right plate). All three plasmids (pDB170, 338, 339) also carry a l cZ gene f r additional
isual selection on top of kanamycin resistance.
To test if the bacteria could survive by means of the retained MapA activity, we performed a similar
experiment with the double deletion mutant mDB130 (∆mapA:loxP;∆mapB:zeocin; attp:mapB:hygromycin).
We attempted to replace the wt mapB gene at the attP site with the three low-activity mapB mutants,
however for ease of identification of true transformants from background colonies, we used plasmids
with LacZ activity (pDB338 for mapBV18G; pDB339 for mapBW255L; pDB340 for mapBV18G,W255L). Again,
both mapBV18G and apBW255L produced multiple viable colonies (Figure 6, bottom) which did not
show any apparent growth defect in comparison to wt.
Ho ever, only one blue colony was detectable with the extremely low-activity MetAPB variant
mapBV18G;W255L and it was designated DB180. The colony appeared after a 12 week incubation.
Preliminary analysis suggested that the clone as a true gene-replacement mutant with a mapBV18G;W255L
genotype as the colony was blue hen plated on Xgal, the antibiotic resistance changed from hygromycin
to kanamycin and a PCR pattern was consistent with a cassette exchange (Supplementary Figure
S3). However, while PCR-based sequencing the apB gene yielded equivocal results, whole genome
sequencing found the mutant to be multiploid (up to 14 copies) in regards to the lacZ, kanamycinR
and mapB genes. Among the mapB gene copies, approximately half of the genes correspond to the
mapBV18G,W255L genotype, while the other half of the sequences were mapBW255L, a genotype that was
already shown to be fully viable. Thus, we conclude that on the background of mapA deletion, in
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contrast to wt background, a very-low activity MapB variant is insufficient to sustain bacterial growth.
This suggested some, however not full, redundancy and mutual compensation between mapA and
mapB. When mapA was present, the 8% activity of MapBV18G,W255L was sufficient for viability and
normal growth, whereas bacteria without mapA could retrieve no viable colonies.
4. Discussion
As noted in the introduction, new drug targets are needed to combat tuberculosis and drug target
validation is important in order to invest efforts into the development of effective drugs. Genes that
code for essential enzymes are attractive targets since enzyme inhibition is a feasible drug-discovery
task [18]. Therefore, correct identification of these genes/enzymes is important.
The MetAP pathway is thought to be vital in all life forms [19–21] and this was specifically shown
in many bacteria [5,6]. The basis for the essentiality of MetAP activity is not completely clear, however
it appears that the removal of the Methionine is a prerequisite for other protein modifications such as
N-myristoylation (probably only existing in eukaryotes) and N-alpha acetylation [22], and affects the
stability and half-life of the protein [23,24]. As a first step for drug design, it might be important to
gain more clarity about the essential gene, even in a small gene family. Here we provide unambiguous
genetic proof that in fact mapA is dispensable, whereas mapB is essential. Our data are supported by
a transposon library analysis previously performed [9] and contradicts a chemical-inhibition assay
(Olaleyle et al.) [10]. We do not have an obvious explanation as to why the carefully performed,
well-designed study by Olaleye suggested other essentiality results, however this may be another
example where results from chemical inhibition may differ from those obtained in genetic deletion
experiments [25]. It is not excluded that MapA is indeed more robust than MapB, however the protein
substrates of MapB may be more important than those of MapA (if they differ at all, a matter which is
unknown). Interestingly, most microorganisms have only one map gene which is usually a MetAP1a
(meaning a homologue of Mtb mapA and not mapB) [26], suggesting that mapA could be sufficient for
cell viability—a suggestion refuted in M. bovis by our findings.
It is unclear why it is that mapB is essential in Mtb, considering both MapB and MapA have
MetAP activity (and that of MapA was shown to be even more robust than that of MapB) [8]. There
are many hypothetical explanations for the differential requirement/essentiality of the two MetAP
isoforms: Interactions with other proteins, a subset of proteins only affected by MapB and not by MapA,
additional as-yet unidentified roles of these enzymes or a different affinity to the ribosome [27]. It was
suggested that MetAPs played an important role in methionine turnover in the cell [28]. Still, it does
not explain why one isoform is essential and the other not. Also, if this is the case, then methionine
supplementation could perhaps salvage a full deletion mutant—however, a previous experiment
reported the opposite [28].
Also, the relation between Peptide deformylase (PDF, encoded by def, Rv0429c) and MAP genes
was not investigated. PDF, which removes the formyl group from the initiating methionine before
the methionine itself is removed by MAP, is considered to be essential according to the analysis of a
transposon library [9] and also by chemical inhibition in eukaryotic cells [23]. Since PDF activity is
an absolute prerequisite for MetAP activity, the vital importance of MetAP explains the essentiality
of PDF (def ). Indeed, in previous experiments, a def deletion mutant in mycobacteria could only be
created on the background of an inactivating mutation in formyl tRNAfMet formyltransferase [29],
making the removal of the formyl group unnecessary for the activity of MetAP.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/5/393/s1,
Figure S1: Confirmation of a mapA deletion mutant. Figure S2: Failure to completely delete mapB from the
genome. Figure S3: The exchange in attb cassettes from pDB271 (mapBwt, hygR) to pDB340 (mapBV18G,W255L, lacZ +
, kanamycinR) between mDB130 and mDB180. Supplementary Table S1: Plasmid table, primer table, mutant list.
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